Continue reading here:
AzurRx BioPharma Provides Insight into Drawbacks of Using Porcine Products in Production of Pharmaceuticals and Medicinals, Offers Update on Efforts...
Related Post
- AssistRx Joins Inaugural Drug Channels Leadership Forum as Diamond Sponsor - November 12th, 2024
- Collegium to Participate in Upcoming Investor Conferences - November 12th, 2024
- Araris Biotech Publishes Foundational Science Behind its Novel Antibody-Drug Conjugate Platform in ChemBioChem - November 12th, 2024
- Kailera Therapeutics Appoints Scott M. Akamine as Chief Legal Officer - November 12th, 2024
- Intercept Receives Complete Response Letter from FDA Addressing OCALIVA supplemental New Drug Application (sNDA) - November 12th, 2024
- Nkarta to Participate in an Upcoming Investor Conference - November 12th, 2024
- Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer - November 12th, 2024
- Vosita Announces New Features and Exciting Giveaway - November 12th, 2024
- Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual... - November 12th, 2024
- Mustang Bio Receives Positive Listing Determination from Nasdaq - November 12th, 2024
- Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108 - November 12th, 2024
- Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq - November 12th, 2024
- Gelteq Expands Operations in United States with Appointment of Adam Bendell as President of U.S. Operations to Scale Domestic Business - November 12th, 2024
- Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product... - November 12th, 2024
- Capricor Therapeutics to Present Exosome Platform Updates at 2024 American Association of Extracellular Vesicles Annual Meeting - November 12th, 2024
- Vincerx Pharma Reports Third Quarter 2024 Financial Results - November 12th, 2024
- Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update - November 12th, 2024
- Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment - November 12th, 2024
- SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference - November 12th, 2024
- Sparian Biosciences Announces Results from the Phase 1 Clinical Trial of First in Class Novel Arylepoxamide Receptor (AEAr) Agonist Analgesic SBS-1000 - November 12th, 2024
- Kineta Updates KVA12123 Clinical Results from Ongoing Phase 1/2 VISTA101 Study at Society for Immunotherapy of Cancer (2024) - November 10th, 2024
- CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup - November 10th, 2024
- Medigene Presents Unique Approach for Use of Optimal T Cell Receptors in TCR-Guided Modalities at Cell 2024 - November 10th, 2024
- Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2024 - November 10th, 2024
- Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for... - November 10th, 2024
- Ardelyx Responds to District Court Decision Granting Motion to Dismiss - November 10th, 2024
- Io Therapeutics, Inc., announces presentation of data on its RAR gamma agonist compound IRX5010 demonstrating inhibition of tumor infiltrating myeloid... - November 10th, 2024
- Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the... - November 10th, 2024
- Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued... - November 10th, 2024
- Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting - November 10th, 2024
- Aptose Reports Results for the Third Quarter 2024 - November 10th, 2024
- PacBio to Present at Upcoming Investor Conferences - November 10th, 2024
- Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates - November 10th, 2024
- Teva to Present at the Jefferies London Healthcare Conference - November 10th, 2024
- Bionomics Provides an Update on Re-domiciliation via Scheme of Arrangement - November 10th, 2024
- Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates... - November 10th, 2024
- Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the... - November 10th, 2024
- InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 10th, 2024
- Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid... - November 10th, 2024
- Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration... - November 10th, 2024
- Rani Therapeutics to Participate in Upcoming Investor Conferences - November 8th, 2024
- SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2024 - November 8th, 2024
- Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates - November 8th, 2024
- Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024 - November 8th, 2024
- PacBio Announces Third Quarter 2024 Financial Results - November 8th, 2024
- Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update - November 8th, 2024
- Kura Oncology Reports Third Quarter 2024 Financial Results - November 8th, 2024
- Spero Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 14, 2024 - November 8th, 2024
- Senseonics Holdings, Inc. Reports Third Quarter 2024 Financial Results - November 8th, 2024
- GENFIT Reports Third Quarter 2024 Financial Information - November 8th, 2024
- TELA Bio Reports Third Quarter 2024 Financial Results - November 8th, 2024
- Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - November 8th, 2024
- CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - November 8th, 2024
- Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results - November 8th, 2024
- Dyne Therapeutics to Present at Upcoming Investor Conferences - November 8th, 2024
- Biora Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update - November 8th, 2024
- Notice of General Meeting - November 8th, 2024
- BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates - November 8th, 2024
- CORRECTION - 23andMe to Report Q2 FY2025 Financial Results - November 8th, 2024
- Cytek® Biosciences Becomes First Company to Add Ability to Detect Subcellular Particles to Its Cell Sorter - November 8th, 2024
- Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD - October 30th, 2024
- Tevogen Bio Signs Letter of Intent With CD8 Technology to Build Up to a $50 Million R&D and Manufacturing Facility; No Impact on Shareholder Equity - October 30th, 2024
- Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile - October 30th, 2024
- Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business Update - October 30th, 2024
- Tevogen Bio Reports Nasdaq Listing Compliance as CEO Reaffirms His Commitment in Bridging the Information Gap About the Company - October 30th, 2024
- BioVie Inc. Announces Closing of Registered Direct Offering - October 30th, 2024
- Shuttle Pharma Pays Off Senior Secured Convertible Note - October 30th, 2024
- ADMA Biologics to Report Third Quarter 2024 Financial Results on November 7, 2024 - October 30th, 2024
- Cytek Biosciences to Report Third Quarter 2024 Financial Results on November 5, 2024 - October 30th, 2024
- Beyond Air® Schedules Second Fiscal Quarter 2025 Financial Results Conference Call and Webcast - October 30th, 2024
- Cronos Group Inc. to Hold 2024 Third Quarter Earnings Conference Call on November 12, 2024 - October 30th, 2024
- Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024 - October 30th, 2024
- MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call - October 30th, 2024
- Neuronetics to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call - October 30th, 2024
- Harvard Bioscience Schedules Third Quarter 2024 Earnings Conference Call for November 7, 2024 at 8:00 AM ET - October 30th, 2024
- Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights - October 30th, 2024
- Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development - October 30th, 2024
- Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and... - October 30th, 2024
- BioAdaptives, Inc. Letter to Shareholders Regarding the Reverse Stock Split - October 30th, 2024
- Enzo Biochem Reports Fourth Quarter and Fiscal Year 2024 Results and Announces Cash Dividend - October 30th, 2024
Recent Comments